Lexeo Therapeutics announced positive interim Phase I/II data for LX2020 in PKP2-associated arrhythmogenic cardiomyopathy, showing an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) in high-dose cohorts. The company also reported that the FDA is open to using NSVT as a primary surrogate endpoint to support potential accelerated approval in a planned pivotal study.
“The magnitude and consistency of NSVT reduction far exceed what available therapies have historically achieved, underscoring how LX2020 could meaningfully improve outcomes for individuals with PKP2-ACM.”
R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics
Lexeo Therapeutics Signs $8.3M M&A Deal with Mantle Therapeutics Inc.
Lexeo Therapeutics completed its acquisition of Mantle Therapeutics for an upfront consideration of $5.3 million in cash and $3.0 million in common stock. The deal includes contingent payments of up to $13.0 million, consisting of a $1.0 million cash payment and $12.0 million in development and regulatory milestones over a 12-year term.
Lexeo Therapeutics Signs $8.3M M&A Deal with Mantle Therapeutics Inc.
Lexeo Therapeutics entered into a definitive agreement to acquire Mantle Therapeutics for an upfront purchase price of $5.3 million in cash and $3.0 million in common stock. The deal includes up to $12.0 million in contingent development and regulatory milestone payments plus a $1.0 million cash payment upon specific events, aimed at expanding Lexeo's Friedreich ataxia (FA) pipeline with new CNS-targeted modalities.